Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Revenue (2016 - 2025)

Fortress Biotech (FBIO) has 12 years of Revenue data on record, last reported at $17.0 million in Q3 2025.

  • For Q3 2025, Revenue rose 16.38% year-over-year to $17.0 million; the TTM value through Sep 2025 reached $5.6 million, up 106.8%, while the annual FY2024 figure was $1.5 million, 71.31% down from the prior year.
  • Revenue reached $17.0 million in Q3 2025 per FBIO's latest filing, up from $16.4 million in the prior quarter.
  • Across five years, Revenue topped out at $21.1 million in Q3 2021 and bottomed at -$41.0 million in Q4 2024.
  • Average Revenue over 5 years is $9.3 million, with a median of $15.3 million recorded in 2023.
  • The widest YoY moves for Revenue: up 2913.17% in 2023, down 343.02% in 2023.
  • A 5-year view of Revenue shows it stood at $18.3 million in 2021, then decreased by 10.24% to $16.4 million in 2022, then crashed by 343.02% to -$39.9 million in 2023, then decreased by 2.88% to -$41.0 million in 2024, then skyrocketed by 141.51% to $17.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $17.0 million in Q3 2025, $16.4 million in Q2 2025, and $13.1 million in Q1 2025.